Actinin-4 protein overexpression as a predictive biomarker in adjuvant chemotherapy for resected lung adenocarcinoma

Biomarkers in Medicine

Volumn 11, Issue 9, 2017, Pages 721-731

  Shiraishi, Hideaki ^a,b   Fujiwara, Yutaka ^a   Kakuya, Takanori ^c   Tsuta, Koji ^a   Motoi, Noriko ^a   Miura, Nami ^c   Watabe, Yukio ^c   Watanabe, Shun Ichi ^a   Noro, Rintaro ^c   Nagashima, Kengo ^d   Huang, Wilber ^e   Yamada, Tesshi ^c   Asamura, Hisao ^f   Ohe, Yuichiro ^a,b   Honda, Kazufumi ^c,g  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b JUNTENDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^d CHIBA UNIVERSITY   (Japan)

^e Abnova Taiwan Corporation   (Taiwan)

^f KEIO UNIVERSITY   (Japan)

^g JAPAN AGENCY FOR MEDICAL RESEARCH AND DEVELOPMENT   (Japan)

Author keywords

actinin 4 (ACTN4); adjuvant chemotherapy; predictive biomarker

Indexed keywords

ALPHA ACTININ 4; CARBOPLATIN; CISPLATIN; DOCETAXEL; PACLITAXEL; VINORELBINE TARTRATE; ACTININ; ACTN4 PROTEIN, HUMAN; ANTINEOPLASTIC AGENT; TUMOR MARKER;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG RESECTION; MAJOR CLINICAL STUDY; MALE; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SURVIVAL TIME; AREA UNDER THE CURVE; GENETICS; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RECEIVER OPERATING CHARACTERISTIC; VERY ELDERLY;

ACTININ; ADENOCARCINOMA OF LUNG; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; BIOMARKERS, TUMOR; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; ROC CURVE;

EID: 85029783329     PISSN: 17520363     EISSN: 17520371     Source Type: Journal    
DOI: 10.2217/bmm-2017-0150     Document Type: Article

References (26)

1. Goldstraw P, Crowley J, Chansky K et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J. Thorac. Oncol. 2(8), 706-714 (2007).
2. Lyons G, Quadrelli S, Jordan P, Colt H, Chimondeguy D. Clinical impact of the use of the revised International Association for the Study of Lung Cancer staging system to operable non-small-cell lung cancers. Lung Cancer 74(2), 244-247 (2011).
3. Arriagada R, Bergman B, Dunant A et al. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N. Engl. J. Med. 350(4), 351-360 (2004).
4. Winton T, Livingston R, Johnson D et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N. Engl. J. Med. 352(25), 2589-2597 (2005).
5. Douillard JY, Rosell R, De Lena M et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol. 7(9), 719-727 (2006).
6. Butts CA, Ding K, Seymour L et al. Randomized Phase III trial of vinorelbine plus cisplatin compared with observation in completely resected stage IB and II non-small-cell lung cancer: updated survival analysis of JBR-10. J. Clin. Oncol. 28(1), 29-34 (2010).
7. Pisters KM, Evans WK, Azzoli CG et al. Cancer Care Ontario and American Society of Clinical Oncology adjuvant chemotherapy and adjuvant radiation therapy for stages I-IIIA resectable non small-cell lung cancer guideline. J. Clin. Oncol. 25(34), 5506-5518 (2007).
8. Pignon JP, Tribodet H, Scagliotti GV et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J. Clin. Oncol. 26(21), 3552-3559 (2008).
9. Beer DG, Kardia SL, Huang CC et al. Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat. Med. 8(8), 816-824 (2002).
10. Bianchi F, Nuciforo P, Vecchi M et al. Survival prediction of stage I lung adenocarcinomas by expression of 10 genes. J.Clin. Invest. 117(11), 3436-3444 (2007).
11. Chen HY, Yu SL, Chen CH et al. A five-gene signature and clinical outcome in non-small-cell lung cancer. N. Engl. J. Med. 356(1), 11-20 (2007).
12. Zhu CQ, Ding K, Strumpf D et al. Prognostic and predictive gene signature for adjuvant chemotherapy in resected non-small-cell lung cancer. J. Clin. Oncol. 28(29), 4417-4424 (2010).
13. Lau SK, Boutros PC, Pintilie M et al. Three-gene prognostic classifier for early-stage non-small-cell lung cancer. J. Clin. Oncol. 25(35), 5562-5569 (2007).
14. Potti A, Mukherjee S, Petersen R et al. A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer. N. Engl. J. Med. 355(6), 570-580 (2006).
15. Honda K, Yamada T, Endo R et al. Actinin-4, a novel actin-bundling protein associated with cell motility and cancer invasion. J. Cell. Biol. 140(6), 1383-1393 (1998).
16. Hayashida Y, Honda K, Idogawa M et al. E-cadherin regulates the association between beta-catenin and actinin-4. Cancer Res. 65(19), 8836-8845 (2005).
17. Watabe Y, Mori T, Yoshimoto S et al. Copy number increase of ACTN4 is a prognostic indicator in salivary gland carcinoma. Cancer Med. 3(3), 613-622 (2014).
18. Yamamoto S, Tsuda H, Honda K et al. Actinin-4 expression in ovarian cancer: a novel prognostic indicator independent of clinical stage and histological type. Mod. Pathol. 20(12), 1278-1285 (2007).
19. Honda K, Yamada T, Hayashida Y et al. Actinin-4 increases cell motility and promotes lymph node metastasis of colorectal cancer. Gastroenterology 128(1), 51-62 (2005).
20. Greene FL, Sobin LH. A worldwide approach to the TNM staging system: collaborative efforts of the AJCC and UICC. J. Surg. Oncol. 99(5), 269-272 (2009).
21. Mcshane LM, Altman DG, Sauerbrei W et al. Reporting recommendations for tumor marker prognostic studies (REMARK). J. Natl Cancer Inst. 97(16), 1180-1184 (2005).
22. Noro R, Honda K, Tsuta K et al. Distinct outcome of stage I lung adenocarcinoma with ACTN4 cell motility gene amplification. Ann. Oncol. 24(10), 2594-2600 (2013).
23. Kikuchi S, Honda K, Tsuda H et al. Expression and gene amplification of actinin-4 in invasive ductal carcinoma of the pancreas. Clin. Cancer Res. 14(17), 5348-5356 (2008).
24. Wang MC, Chang YH,Wu CC et al. Alpha-actinin 4 is associated with cancer cell motility and is a potential biomarker in non-small cell lung cancer. J. Thorac. Oncol. 10(2), 286-301 (2015).
25. Miura N, Kamita M, Kakuya T et al. Efficacy of adjuvant chemotherapy for non-small cell lung cancer assessed by metastatic potential associated with ACTN4. Oncotarget 7(22), 33165-33178 (2016).
26. Noro R, Ishigame T, Walsh N et al. A two-gene prognostic classifier for early-stage lung squamous cell carcinoma in multiple large-scale and geographically diverse cohorts. J. Thorac. Oncol. 12(1), 65-76 (2016).